Establishment Labs (NASDAQ:ESTA) Sets New 52-Week High – What’s Next?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) reached a new 52-week high on Monday . The company traded as high as $97.59 and last traded at $95.11, with a volume of 144133 shares trading hands. The stock had previously closed at $92.54.

Wall Street Analysts Forecast Growth

ESTA has been the subject of several analyst reports. Citigroup raised their target price on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. BTIG Research reaffirmed a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Mizuho raised their price target on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Finally, TD Cowen upped their price objective on Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $93.75.

Establishment Labs Stock Up 2.0%

The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The stock has a market cap of $2.78 billion, a P/E ratio of -63.50 and a beta of 1.07. The company’s 50 day moving average price is $85.77 and its two-hundred day moving average price is $73.97.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter in the previous year, the business earned ($0.70) earnings per share. The company’s revenue for the quarter was up 44.7% compared to the same quarter last year. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Institutional Trading of Establishment Labs

A number of hedge funds have recently added to or reduced their stakes in ESTA. Goldman Sachs Group Inc. lifted its position in shares of Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares during the period. Viking Global Investors LP purchased a new stake in shares of Establishment Labs during the 2nd quarter worth $14,669,000. Soleus Capital Management L.P. bought a new stake in Establishment Labs during the second quarter valued at about $9,050,000. Summit Partners Public Asset Management LLC raised its holdings in Establishment Labs by 87.1% in the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after purchasing an additional 200,255 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its holdings in shares of Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after buying an additional 197,962 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.